Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933928 | 0.92 | EGLN1 (0.46) | — | |
| SCHEMBL11934001 | 0.87 | PTPRC (0.41) | CA12CA9 | |
| SCHEMBL16247701 | 0.81 | HSD17B10 (0.48) | CA12CA9ALOX15ALOX12MAOB | |
| SCHEMBL934174 | 0.81 | — | — | |
| SCHEMBL11934016 | 0.80 | LDHA (0.41) | CA12CA9ALOX15ALOX12MAOB | |
| SCHEMBL933166 | 0.80 | — | — | |
| SCHEMBL934353 | 0.79 | EGLN1 (0.46) | — | |
| SCHEMBL933990 | 0.79 | HIF1A (0.50) | — | |
| SCHEMBL11934008 | 0.78 | PRKDC (0.44) | — | |
| SCHEMBL11934011 | 0.77 | PTPRC (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238637-B2 | Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof | BEIJING BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-19 | — | — | US | disclosed |
| US-20140343137-A1 | Stable Polymorphic Forms of Compound as Hypoxia Mimetics, and Uses Thereof | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343137-A1 | Stable Polymorphic Forms of Compound as Hypoxia Mimetics, and Uses Thereof | HIF1A, HIF1AN, COXFA4L2 | CA12 713/4885CA9 1195/4885ALOX15 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.